Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Medical Tourism Loans for Lu-177 DOTATATE PRRT in India
Neuroendocrine tumor patients from the Gulf, Africa, and beyond are traveling to India for Lu-177 DOTATATE (PRRT) therapy at a fraction of what the same treatment costs elsewhere. This guide covers the real financing options - from medical loans and insurance pre-authorization to hospital payment plans and family pooling - and what a complete budget actually looks like.
Dry Mouth and Oral Soreness During Lu-177 PSMA Therapy
Dry mouth is one of the most commonly reported side effects of Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer. This article explains why salivary glands are affected, how severe symptoms usually are, and what oral-care and nutritional strategies can keep you more comfortable across your treatment cycles.
Lu-177 DOTATATE PRRT Cost: India vs UAE for GCC NET Patients
GCC patients with gastroenteropancreatic neuroendocrine tumors face a significant cost gap between India and the UAE for Lu-177 DOTATATE PRRT. This guide breaks down real pricing, quality standards, and how to plan your treatment journey from the Gulf.
Bone Marrow Suppression and Low Blood Counts During Lu-177 PSMA Therapy: What Causes It, When It Is Dangerous, and How to Stay Safe
Low blood counts are a known but manageable side effect of Lu-177 PSMA therapy for metastatic prostate cancer. Learn what causes myelosuppression, which warning signs need same-day attention, and how your care team keeps you safe across each treatment cycle.
Radiation Safety After Lu-177 PSMA Therapy: Your Complete Guide to Precautions, Contamination Risks, and Safe Return to Daily Life
After each Lu-177 PSMA infusion, your body carries low-level radiation for a short period. These practical precautions - most lasting just a few days - protect the people you live with while you recover at home.
When Lu-177 DOTATATE Stops Working: Progressive Disease and Treatment Resistance in Advanced GEP-NET - What to Do Next
When lutetium Lu-177 dotatate (PRRT) stops controlling a gastroenteropancreatic neuroendocrine tumor, progression is not the end of the road. This guide covers the most recognized next-line options - re-treatment, everolimus, sunitinib, alpha therapy trials, and liver-directed care - and explains how to work with your team to find the right path.
Lu-177 DOTATATE (PRRT) in Saudi Arabia: Cost, Availability, and How to Access Treatment in India
If you have a neuroendocrine tumor and live in Saudi Arabia, PRRT with lutetium Lu-177 dotatate is rarely available close to home. This guide explains what treatment costs in India versus the United States, whether you are likely eligible, and how to start the process of accessing care abroad.
Lu-177 PSMA vs Radium-223 for Bone Metastases in mCRPC: How to Choose Between Two Targeted Radiation Therapies
If your prostate cancer has spread to bone and hormone therapy is no longer holding it back, two targeted radiation options may be on the table: Lu-177 PSMA and radium-223. This guide explains how they differ, who each one suits, and what to ask before you decide.
Your First PRRT Consultation and Screening Appointment: What Happens During Eligibility Evaluation, What to Bring, and How to Prepare for Lu-177 DOTATATE Treatment in India
If you have a neuroendocrine tumor and are heading to India for PRRT, your first step is an eligibility evaluation. This article explains exactly what that appointment involves, what documents to bring, and how to prepare before you travel.
Choosing a Lu-177 PSMA Treatment Center in India: How to Evaluate Quality, Credentials, Track Record, and Cost
Not every hospital offering Lu-177 PSMA therapy in India delivers the same standard of care. This guide covers eight quality markers that matter most - from AERB licensing and PSMA-PET capability to case volume and cost transparency - so you can choose the right center before you travel.
Getting a Second Opinion on Lu-177 PSMA Eligibility Before You Commit to Treatment: What to Prepare and How the Expert Review Works
If your oncologist has not discussed Lu-177 PSMA therapy as a possible next step after standard treatment, a formal eligibility review may reveal options you have not yet considered. Here is what to gather and how the specialist review process actually works.
Neuroendocrine Tumor with Liver Metastases: Are You Eligible for Lu-177 DOTATATE When You Have Hepatic Disease?
Liver metastases are very common in GEP-NETs - but they do not automatically disqualify you from Lu-177 DOTATATE therapy. Here is what the evidence shows about hepatic tumor burden, liver function tests, and PRRT eligibility.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.